GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The UK company buys IRDx for $1bn.
